

Third Year MBBS 2023 Study

Guide

Cardiovascular & Respiration Module-VI

Date: 31st July, 2023 by DME,, New Teaching Block

1 | P a g e

| Table of Contents | |
|--|--------------------|
| CVS & Resp Module Team | 5 |
| University Moto, Vision, Values & Goals | 6 |
| Module VI – CVS & Resp Module | 7 |
| SECTION - I Terms & Abbreviations | |
| Teaching and Learning Methodologies / Strategies | 9 |
| SECTION- II b Learning Objectives, Teaching Strategies & Assessments of Pharmacology, Forensic medicine, Pathology, Medicine, Surgery, Gynae/obs, Family Medicine | |
| Clinically Integrated Learning Objectives | |
| Self-Directed Learning (SDL) | 27 |
| SECTION-III | |
| Integrated Module Time Table | |
| Teaching hours Summary | |
| Venues for Academic Session | |
| SECTION IV: Assessment Policies | 40 |
| Assessment plan | 41 |
| Types of Assessment: Learning Resources | |
| SECTION V | |
| SECTION VI | |
| Table of Specification (TOS) For CVS & Resp Module Assessment for Third Year MBBS Modules during running academic session: | |
| | 2 P a g e |

Date: 31st July, 2023 by DME,, New Teaching Block


| Annexure I4 | 8 |
|---|---|
| (Sample MCQ & SEQ papers with analysis) | 9 |
| Annexure II | 1 |

CVS & Respiration Module Team

| Duration of module | : | 06 Weeks |
|--------------------|---|------------------------------------|
| Coordinator | : | Dr. Filza .Ali |
| Co-coordinator | : | Dr.Naila Batool / Dr. Raheel. Baig |
| Review by | : | Module Committee |

| | Module Committee | | | | Module Task Force Team |
|-----|--|----------------------------------|----|---|--|
| 1. | Vice Chancellor RMU | Prof. Dr. Muhammad Umar | 1 | Coordinator | Dr. Attiya Munir (Assissant Professor of Pharmacology) |
| 2. | Director DME | Prof. Dr. Rai Muhammad Asghar | 2 | DME Focal Person | Dr. Maryum Batool |
| 3. | Convener Curriculum | Prof. Dr. Naeem Akhter | 3 | Co-coordinator | Dr. Omaima, Dr Haseeba (Demonstrator of Pharmacology) |
| 4. | Dean Basic Sciences | Prof. Dr. Ayesha Yousaf | | | |
| 5. | Additional Director DME | Prof. Dr. Ifra Saeed | | | |
| 6. | Chairperson Pharmacology & Implementation Incharge 3 rd year MBBS | Dr. Asma Khan | | | |
| 7. | Chairperson Pathology | Prof. Dr. Mobina Dhodhy | | | |
| | | | 1. | Director DME | Prof. Dr. Rai Muhammad Asghar |
| 8. | Chairperson Forensic Medicine | Dr Romana Malik | 2. | Add. Director DME | . Dr. Asma Khan |
| 9. | Focal Person Pharmacology | Dr Zunaira Hakim | 3. | Assistant Director DME | Dr Omaima Asif |
| 10. | Focal Person Pathology | Dr Fareeha Afzal | 4. | Module planner & Implementation coordinator | Dr. Omaima Asif |
| 11. | Focal Person Forensic Medicine | Dr. Gulzeb | 5. | Editor | Mr. Ahmed Rafay, Dr. Omaima Asif |
| 12. | Focal Person Medicine | Dr. Saima Ambreen | | | |
| 13. | Focal Person Behavioral Sciences | Dr. Saadia Yasir | | | |
| 14. | Focal Person Community Medicine | Dr. Afifa Kulsoom | | | |
| 15. | Focal Person Quran Translation Lectures | Mufti abdul Wahid | | | |
| 16. | Focal Person Family Medicine | Dr Sadia Khan | | | |
| 17. | Focal Person Bioethics Department | Prof. Dr. Akram Randhawa | | | |
| 18. | Focal Person Surgery | Dr Huma Sabir | | | |

RMU Motto



University Moto, Vision, Values & Goals

Mission Statement

To impart evidence-based research-oriented health professional education in order to provide best possible patient care and inculcate the values of mutual respect, ethical practice of healthcare and social accountability.

Vision and Values

Highly recognized and accredited centre of excellence in Medical Education, using evidencebased training techniques for development of highly competent health professionals, who are lifelong experiential learner and are socially accountable.

Goals of the Undergraduate Integrated Modular Curriculum

The Undergraduate Integrated Learning Program is geared to provide you with quality medical

education in an environment designed to:

- Provide thorough grounding in the basic theoretical concepts underpinning the practice of medicine.
- Develop and polish the skills required for providing medical services at all levels of the Health care delivery system.
- Help you attain and maintain the highest possible levels of ethical and professional conduct in your future life.
- Kindle a spirit of inquiry and acquisition of knowledge to help you attain personal and professional growth & excellence.

Module – VI: CVS & Respiration Module

Introduction: CVS and Respiration module aims to provide students with essential knowledge of pathological processes involved in cardiovascular and respiratory system. Detailed understanding of these is the essence of the study for intelligent clinical practice, presentation/interpretation of diseases & management.

Rationale : The CVS & Respiration module is designed to impart knowledge about the concepts & principles of the basic sciences in context of clinical symptoms & signs of commonly occurring CVS & Respiratory diseases and develop a problem solving approach in diagnosing and management of these diseases.

Module Outcomes

Each student will be able to:

Knowledge

Acquire knowledge about the basic terminologies used in Pharmacology, Pathology & Forensic Medicine as well as the concepts of diseases in the community

- Appreciate concepts & importance of
- Research
- Biomedical Ethics
- Family Medicine
- Artificial Intelligence

Skills

• Interpret and analyze various practical of Pre-clinical Sciences.

Attitude

• Demonstrate a professional attitude, team building spirit and good communication skills.

This module will run in 6 weeks duration. The content will be covered through introduction of topics. Instructional strategies are given in the time table and learning objectives are given in the study guides. Study guides will be uploaded on the university website. Good luck!

Date: 31st July, 2023 by DME,, New Teaching Block

Section I – Terms & Abbreviations

Contents

- Domains of Learning
- Teaching and Learning Methodologies/Strategies
 - Large Group Interactive Session (LGIS)
 - Small Group Discussion (SGD)
 - Self-Directed Learning (SDL)
 - Case Based Learning (CBL)

Tables & Figures

- Table1. Domains of learning according to Blooms Taxonomy
- Figure 1. Prof Umar's Model of Integrated Lecture
- Table2. Standardization of teaching content inSmall Group Discussions
- Table 3. Steps of taking Small Group Discussions

Table1. Domains of learning according to Blooms Taxonomy

| Sr. # | Abbreviation | Domains of learning |
|-------|--------------|--|
| | С | Cognitive Domain: knowledge and mental skills. |
| | C1 | Remembering |
| | C2 | Understanding |
| 1. | C3 | Applying |
| | C4 | Analyzing |
| | C5 | Evaluating |
| | C6 | Creating |
| | Р | Psychomotor Domain: motor skills. |
| | P1 | Imitation |
| 2. | P2 | Manipulation |
| ۷. | P3 | Precision |
| | P4 | Articulation |
| | P5 | Naturalization |
| | А | Affective Domain: feelings, values, dispositions, attitudes, etc |
| | A1 | Receive |
| 3. | A2 | Respond |
| 5. | A3 | Value |
| | A4 | Organize |
| | A5 | Internalize |

Teaching and Learning Methodologies / Strategies

Large Group Interactive Session (LGIS)

The large group interactive session is structured format of Prof Umar Model of Integrated lecture. It will be followed for delivery of all LGIS. Lecturer will introduce a topic or common clinical condition and explains the underlying phenomena through questions, pictures, videos of patients, interviews and exercises, etc. Students are actively involved in the learning process.




Figure 1. Prof Umar's Model of Integrated Lecture

Small Group Discussion (SGD)

This format helps students to clarify concepts acquire skills and attitudes. Sessions are structured with the help of specific exercises such as patient case, interviews or discussion topics or power point presentations. Students exchange opinions and apply knowledge gained from Lectures, SGDs and Self-study. The facilitator role is to ask probing questions, summarize and helps to clarify the concepts.

Table 3.

Steps of taking Small Group Discussions

| Step 1 | Sharing of Learning objectives by using students Study guides | First 5 minutes |
|---------|--|-----------------|
| Step 2 | Asking students pre-planned questions from previous teaching session to develop co-relation (these questions will be standardized) | 5minutes |
| Step 3 | Students divided into groups of three and allocation of learning objectives | 5minutes |
| Step 4 | ACTIVITY: Students will discuss the learning objectives among themselves | 15 minutes |
| Step 5 | Each group of students will present its learning objectives | 20 min |
| Step 6 | Discussion of learning content in the main group | 30min |
| Step 7 | Clarification of concept by the facilitator by asking structured questions from learning content | 15 min |
| Step 8 | Questions on core concepts | |
| Step 9 | Questions on horizontal integration | |
| Step 10 | Questions on vertical integration | |
| Step 11 | Questions on related research article | |
| Step 12 | Questions on related ethics content | |
| Step 13 | Students Assessment on online MS teams (5 MCQs) | 5 min |
| Step 14 | Summarization of main points by the facilitator | 5 min |
| Step 15 | Students feedback on the SGD and entry into log book | 5 min |
| Step 16 | Ending remarks | 9 Page |

Table 2.

Standardization of teaching content in Small Group Discussions

| S.No | Topics | Approximate % |
|------|---|---------------|
| 1 | Title Of SGD | |
| 2 | Learning Objectives from Study Guides | |
| 3 | Horizontal Integration | 5%+5%=10% |
| 4 | Core Concepts of the topic | 60% |
| 5 | Vertical Integration | 20% |
| 6 | Related Advance Research points | 3% |
| 7 | Related Ethical points | 2% |

Self-Directed Learning (SDL)

- Self- directed learning is a process where students take primary charge of planning, continuing and evaluating their learning experiences.
- Time Home assignment
- Learning objectives will be defined
- Learning resources will be given to students : Text book (page no), web site
- Assessment: Will be online on LMS (Mid module/ end of Module)

Case Based Learning (CBL)

- It's a learner centered model which engages students in discussion of specific scenarios that resemble typically are real world examples.
- Case scenario will be given to the students
- Will engage students in discussion of specific scenarios that resemble or typically are real-world examples.
- Learning objectives will be given to the students and will be based on
 - i. To provide students with a relevant opportunity to see theory in practice
 - ii. Require students to analyze data in order to reach a conclusion.
- iii. Develop analytic, communicative and collaborative skills along with content knowledge.

Section-II:

Learning Objectives, Teaching Strategies & Assessments

Contents

- Horizontally Integrated Clinical Sciences (Pharmacology, Pathology & Forensic Medicine)
- Large Group Interactive Session:
 - Pharmacology (LGIS)
 - Pathology (LGIS)
 - Forensic Medicine (LGIS)
- Small Group Discussions
 - Pharmacology (SGD)
 - Pathology (SGD)
 - Forensic Medicine (SGD)
- Self-Directed Topic, Learning Objectives & References
 - Pharmacology(SDL)
 - Pathology (SDL)
 - Forensic Medicine (SDL)
 - Practical
 - Vertical horizontal integration Medicine & Allied
 - Surgery & Allied

Learning Objectives

| | Week 1 | | | | | | | | |
|---------|---|--------------------|--|--|---------------------|----------------------|--|--|--|
| Code No | Торіс | Discipline | At the end of the lecture student should be able to | C/P/A | Teaching strategies | Assessmen t tools | | | |
| L-1 | Thanatology- I (Introduction & Types of death Immediate & Early changes of death) | Forensic Medicine | Define death and Classify its types State the WHO criteria & and indicators to diagnose death Briefly describe the the causes, manner, mode, mechanisms, medico legal aspects of death Define Algor mortis and state its medico-legal importance Enlist various factors affecting algor mortis. Briefly explain the method to measure the temperature of body after death. Briefly describe Postmortem caloricity. | C1 C1 C2 C2 C2 C2 C2 | LGIS | MCQ SEQs VIVA | | | |
| L-2 | Thanatology- II (Livor mortis & Rigor mortis) | Forensic Medicine | Define Livor mortis and state its medico legal importance Differentiate between Livor mortis and bruise. State the mechanism of Rigor Mortis in the body after death and its medico legal importance Enumerate the factors which modify the onset & duration of rigor mortis Enlist the conditions simulating rigor mortis and differentiate them | C1 C3 C2 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA | | | |
| L-3 | Concept of environment & water | Community Medicine | Define safe wholesome water Describe sources of water supply Explain water pollution, pollutants, indicators of water pollution Differentiate between shallow and deep wells Enlist guidelines for drinking water quality Elaborate concepts of water | C1 C2 C4 C1 C2 | LGIS | MCQ SEQs VIVA | | | |
| L-4 | Approach to a patient with chronic Peripheral arterial Disease | Surgery | Recall the vascular anatomy and histology briefly. Briefly describe the features of chronic peripheral occlusive arterial disease. Enlist the investigations and state treatment options for occlusive arterial disease. Explain the principles of management of the chronic ischemic limb and role of surgery . | C1 C2 C2 C3 | LGIS | MCQs SEQs VIVA | | | |
| L-5 | Artherosclerosis Pathogenesis and morphology | Pathology | Classify risk factors for atherosclerosis Describe the role of endothelium in pathogenesis of atheromatous plaque Describe the role of vessel smooth muscles in pathogenesis of atheromatous plaque Describe the roll of endothelium in pathogenesis of atheromatous plaque Describe the roll of extracellular matrix in pathogenesis of atheromatous plaque Describe the morphology of atheromatous plaque | C3 C2 C2 C2 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA | | | |

| | 1 | | | | | |
|------|---|--------------------|--|--|------|----------------------|
| L-6 | Anti-hypertensive I (Introduction and classification) | Pharmacology | Define hypertension Classify anti-hypertensive drugs groups Explain the mechanisms of action of centrally acting antihypertensive drugs | C1 C2 C2 | LGIS | MCQs SEQs VIVA |
| L-7 | Consequences of Atherosclerosis | Pathology | Enlist complications of Atheroma Correlate the consequences of atherosclerosis with clinical features . | C2 C3 | LGIS | MCQs SEQs VIVA |
| L-8 | Water distribution, Conservation and purification | Community Medicine | Define intermittent and continuous system of distribution of water. Define water conservation. Describe hardness of water and types. Explain ways for removal of hardness of water. Describe methods of purification. Enlist artificial and natural methods of purification. Elaborate concepts on purification on large and small scale. | C1 C1 C2 C2 C2 C1 C2 | LGIS | MCQs SEQs VIVA |
| L-9 | Hypertension | Medicine | Define hypertension. Enlist causes of hypertension. Describe clinical manifestations of hypertension including target organ damage. Outline investigations and management of hypertension. Highlight choice of antihypertensive drugs in different comorbidities | C1 C1 C2 C2 C1 | LGIS | MCQs SEQs |
| L-10 | Hypertensive disorders in pregnancy PIH, Preeclampsia | Obstetric | Define hypertension in pregnancy Classify the types of hypertension in pregnancy State the pathophysiology of pre-eclampsia Describe the clinical presentation of pre-eclampsia and understand the principles of its management Enlist and discuss maternal and fetal complications and long term risks to both mother and baby associated with hypertensive disorders | C 1 C 1 C 2 C 3 C 2 | LGIS | MCQs SEQs VIVA |
| L-11 | Antihypertensive II (ACE inhibitors and ARBs) | Pharmacolog | Enlist ACEI and ARB Describe mechanism of action, uses and adverse effects of this groups | C1 C2 | LGIS | MCQs SEQs VIVA |
| L-12 | Air and Ventilation (control of air pollution) | Community Medicine | Enlist indices of thermal comfort Describe the factors responsible for vitiation of air Define air pollution Identify sources of air pollution and air pollutants Demonstrate selection of air sample for analysis Enumerate the methods to prevent & control of air pollution Describe standards and types of ventilation | C1 C2 C1 C3 C4 C1 C1 C1 C2 | LGIS | MCQs SEQs |

| S-1 | Hypertensive Heart Disease | Patholog | Define criteria of systemic hypertensive heart disease Classify the etiological factors of hypertension Differentiate between benign and malignant Hypertension Describe the pathogenic mechanisms of essential hypertension Describe morphology of heart in systemic hypertensive heart disease Describe Morphology of cor –pulmonale Differentiate b/w systemic and pulmonary hypertension Demonstrate clinical reasoning in interpreting the clinical history and symptomatology | C1 C3 C3 C2 C2 C2 C2 C2 C3 A2 | SGD | MCQs SEQs VIVA |
|------|--|--------------------|--|--|------|----------------------|
| L-13 | Air and Ventilation (global warming.) | Community Medicine | Enlist natural and artificial methods of air purification. Describe the green house effect Enlist green house gases. Identify sources of green house gases. Describe global warming. Define ozone hole. Describe link between global warming and climate change. | C1 C2 C1 C3 C2 C1 C2 | LGIS | MCQs SEQs VIVA |

| | | | 2nd Week | | | |
|---------|---|--------------------|---|----------------------------|------------------------|----------------------|
| Code no | Торіс | Discipline | At the end of the lecture student should be able to | C/P/A | Teaching strategies | Assessment tools |
| L-14 | Antihypertensives III (Vasodilators) | Pharmacology | Classify vasodilators Discuss mechanism of action ,clinical uses and side effects of different types of vasodilators | C1 C2 | LGIS | MCQs SEQs VIVA |
| L-15 | Antihypertensives IV (Ca Channel Blockers) | Pharmacolog | Classify calcium channel blockers Discuss mechanism of action ,clinical uses and side effects of calcium channel blockers | C2 C1 | LGIS | PBQS |
| L-16 | Prevention of Radiation Hazards | Community Medicine | Describe sources of radiation exposure Describe types of radiations Discuss biological effects of radiation Discuss radiation protection | C2 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA |
| L-17 | Antianginal I | Pharmacology | Enlist Anti-Anginal Drugs Describe mechanism of action and adverse effects of nitrates | C1 C2 | LGIS | MCQs SEQs VIVA |
| L-18 | Thanatology- III (Late changes of Death Putrefaction) | Forensic Medicine | Enlist the bacteria participates in putrefaction Briefly describe the features of putrefaction and its mechanism State the medicolegal importance of maggots. | C1 C2 C2 1 | LGIS Page | MCQs SEQs VIVA |
| | | | Briefly describe the factors affecting putrefaction in water. | C2 | | |
| S-2 | Pathophysiol ogy of Angina | Pathology | Classify the ischemic heart disease on the basis of pattern of clinical presentation Describe the types of angina Describe the pathophysiology of angina Correlate the pathogenesis of ischemic heart disease with various etiological factors | C3 C2 C2 C3 | SGD | MCQs SEQs VIVA |
| L-19 | Ischemic Heart Disease | Medicine | Classify coronary heartdiseases. Explain clinical manifestation of ischemic heart disease including stable angina, unstable angina, MI and heart failure. Describe investigation of IHD. Outline management of IHD | C1 C2 C2 C3 | LGIS LGIS | MCQs SEQs VIVA |
| L-20 | Antianginal II | Pharmacology | Describe mechanism of action and adverse effects of other anti angina Drugs | C2 | LGIS | MCQs SEQs VIVA |

| C-1 | Diuretics | Pharmacology | Rationalize the use of diuretics in specific clinical scenario | C3 | CBL | MCQs SEQs VIVA |
|------|--------------------------------------|--------------|--|--|-----------------|----------------------|
| L-21 | | | | | | |
| S-3 | Ischemic Heart Disease | Pathology | Describe morphological features of MI Correlate pathogenesis, And Complications of MI. Describe chronic ischemic heart disease Describe the pathogenesis of myocardial infarction Describe the patterns of myocardial infarction Correlate the evolution of morphological changes in myocardial infarction with time duration of infarct Correlate the complications of myocardial infarction with clinical features | C2 C3 C2 C2 C2 C3 C3 | SGD | MCQs SEQs |
| C-2 | Vascuilitis | Pathology | Describe Pathogenesis of vasculitis Clarify Various forms of vasculitis Describe complication of vasculitis Differentiate among Morphological features of various type of vasculitis Interpret the clinical features and lab findings of a case with vasculitis Demonstrate collaborative learning skills Demonstrate adequate communication skills in describing the clinical problem | C2 C3 C2 C3 P2 A3 A3 | CBL | MCQs SEQs |
| L-22 | Cyanotic congenital heart disease | Paediatrics | Define Tetralogy of Fallot Describe the haemodynamics of the defect and its clinical presentation Plan investigations, interpret and to take appropriate action Discuss medical and surgical Management Assess for complications and their management | C1 C2 C2 C3 C3 1 | LGIS : Page | MCQs SEQs VIVA |

| L-23 | Approach to a patient with Gangrene and Amputations | Surgery | Recall the causes of acute limb ischemia. State definition of thromboembolism. Describe the Pathophysiology of Thromboembolism . Discuss the various types of Gangrene. Explain the types of amputations according to ischemia site in a patient. | | LGIS | PBQS |
|------|---|-------------------|--|----------------------|-----------|----------------------|
| L-24 | Thanatology- IV Adipocere, Mummification Estimation of time since death | Forensic Medicine | Define Adipocere and state its medicolegal importance. Define mummification and state its medicolegal importance Briefly describe the method to calculate the time since death. Enumerate different changes after death which helps to calculate the time since death. | | LGIS | MCQs SEQs VIVA |
| L-25 | Acyanotic heart disease | Paediatrics | Describe the haemodynamics of VSD and PDA Discuss the clinical presentation Make Plan of Investigations Discuss the medical and surgical treatment Identify Complications and manage them | | LGIS | MCQs SEQs VIVA |
| L-26 | CCF I (Introduction & classification) | Pharmacology | Classify drug groups used in CCF Describe mechanism of action of digoxin Describe digoxin toxicity and its management | C2 C2 C2 | LGIS | MCQs SEQs VIVA |
| P-1 | P drug and prescription of HTN | Pharmacology | • Clincal pharmacology of anti hypertensive drugs. | C3 | practical | OSPE |
| Р-2 | Cardiac Poisons | Forensic Medicine | Enlist important cardiac poisons, Mention the alkaloids, fatal dose and fatal period along with medicolegal significance of Digitalis and Aconite Briefly describe sign and symptoms and autopsy findings of these poisons. Write down important steps of management of such cases. | | practical | OSPE |
| P-3 | Morphology of vascular lesions | Pathology | Identify the morphological features of Calcification Identify the morphological features of atherosclerosis Identify the morphological features of thrombus Demonstrate collaborative working skills | P3 P3 P3 A3 | practical | OSPE |

| 3rd Week | | | | | | | | |
|----------|---|-------------------|---|--|---------------------|----------------------|--|--|
| Code no | Торіс | Discipline | At the end of the lecture student should be able to | C/P/A | Teaching strategies | Assessment tools | | |
| S-4 | Aneurysms & Dissection | Pathology | Classify aneurysms Correlate the etiological factors with the pathogenic mechanisms of aneurysm formation. Correlate atherosclerosis with abdominal aortic aneurysms Enlist the etiological factors for aortic dissection Describe the morphological features of aortic dissection Differentiate between Type A and Type B aortic dissections. | C3 C3 C3 C1 C2 C3 | SGD | MCQs SEQs VIVA | | |
| L-27 | Rheumatic fever | Medicine | Explain pathogenesis of rheumatic fever. Describe clinical manifestations and JONES criteria for diagnosis of Rheumatic fever Enlist investigations for Rheumatic fever Describe management of acute attack and secondary prevention of Rheumatic fever | C2 C2 C1 C3 | LGIS | MCQs SEQs VIVA | | |
| L-28 | Forensic Serology Trace Evidence Blood, Semen & Saliva | Forensic Medicine | Briefly describe the physical, chemical, microscopic, biochemical, spectroscopic Assessment of blood. Enlist the information gathered from a blood ,saliva & seminal stain. State the Medicolegal importance of blood groups ,secretors and non-secretors. Mention the method to Collect, preserve, and dispatch specimen of blood stain Briefly describe the features of salivary and vomitus stain w.r.t Medicolegal importance | C2 C1 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA | | |
| L-29 | Pathogenesis of Rheumatic Fever Morphological changes in Rheumatic Heart Disease | Pathology | Describe the Pathogenesis of rheumatic fever C2 Describe the Pathogenesis of rheumatic Heart Disease Outline the diagnostic criteria of rheumatic fever Discuss the complications of rheumatic fever Define chronic rheumatic heart disease Describe the morphology of rheumatic heart disease Outline the diagnostic criteria of rheumatic Heart Disease Duscuss the complications of rheumatic Heart Disease Duscuss the complications of rheumatic Heart Disease | C2 C2 C2 C1 C2 C1 C2 C1 C2 C3 C2 | LGIS | MCQs SEQs VIVA | | |
| L-30 | CCF II (Digoxin and related drugs): | Pharmacology | Describe mechanism of action of other drugs used in CCF Enlist their therapeutic uses and adverse effects | C2 C2 | LGIS | PBQs | | |

| L-31 | Infective Endocarditis | Medicine | Describe pathogenesis of Infective Endocarditis. Explain clinical features of Infective Endocarditis and Dukes criteria. Enlist investigation of Infective Endocarditis Outline management of Infective Endocarditis | C2 C2 C1 C3 | LGIS | MCQ SEQ |
|------|---|-----------------|---|--|------|----------------------|
| L-32 | Valvular heart disease | Medicine | Describe rheumatic heart disease with pathogenesis. Describe clinical features of valvular heart disease including mitral stenosis | C2 C2 | LGIS | MCQs SEQs |
| L-33 | Rheumatic fever | Paediatrics | Discuss etiology of rheumatic fever and its diagnostic criteria Briefly describe its clinical features Make plan of investigations and their interpretation State the plan of management and discuss about the prophylaxis of rheumatic fever | C2 C2 C2 C3 | LGIS | MCQs SEQs VIVA |
| L-34 | Introduction to Diuretics | Pharmacology | Classify diuretics Describe the role of diuretics in hypertension Rationalize the use of diuretics in specific clinical scenario | C2 C2 C3 | LGIS | MCQs SEQs VIVA |
| L-35 | IHD/CCF | Family Medicine | Explain the management strategies of a patient with IHD and heart failure in general practice including the psychosocial impact of disease on patient and their families Describe the strategies for prevention of IHD and CCF | C2 C2 | LGIS | MCQs |
| L-36 | Infective Endocarditis | Pathology | Enlist the causes of infective endocarditis Classify infective endocarditis Describe morphology of infective endocarditis Differentiate b/w vegetations of different type of endocarditis | C1 C2 C2 C3 | LGIS | MCQs SEQs VIVA |
| C-3 | Myocarditis & pericarditis | Pathology | Differentiate between various types of pericarditis Correlate the pathogenesis of pericardial effusions with the clinical presentation. Correlate different forms of fluid accumulations in pericardial sac with the underlying pathology. Interpret the lab report of a patient with pericardial effusion Demonstrate the critical thinking attitude needed for applying basic knowledge to a clinical situation Enumerate the causes of myocarditis & pericarditis Describe the morphological features of myocarditis Demonstrate the critical thinking attitude needed for applying basic knowledge to a clinical situation | C3 C3 P3 A3 C1 C2 C2 A3 | CBL | PBQS |
| L-37 | Approach to a patient with DVT and varicose veins | Surgery | Briefly recall the venous anatomy and the physiology of venous return. Describe the etiology and pathophysiology of deep venous thrombosis. State the clinical significance and management of varicose veins. | C1 C2 C3 | LGIS | MCQs SEQs VIVA |
| L-38 | Childhood Asthma | Paediatric | Define Asthma and Identify risk factors Discuss clinical presentation and Classify as per GINA guidelines Make differential diagnosis Plan pertinent investigations, interpret and take appropriate action Discuss the treatment of Acute Attack of Asthma and long term management | C1 C2 C1 C3 C2 | LGIS | PBQS |

| L-39 | Antiarrhythmic drugs I (Introduction to normal rhythm and classification) | Pharmacology | Classify antiarrythmic drugs | C2 | LGIS | MCQs SEQs VIVA |
|------|---|-------------------|---|----------------------------|-----------|----------------------|
| L-40 | Antiarrythmic drugs II (class I and class II) | Pharmacology | • Describe mode of action, clinical uses and adverse effects of Class I, Class II antiarrythmic drugs | C1 | LGIS | MCQs SEQs VIVA |
| L-41 | Gestational diabetesmellitus | Obstetrics | Define gestational diabetes mellitus Describe the pathogenesis of GDM Identify and state the risks factor associated with GDM Screen and diagnose GDM Briefly explain the management of GDM | CI C2 C2 C1 C3 | LGIS | MCQs SEQs |
| P-4 | P drug and prescription of angina | Pharmacology | Discuss clinical pharmacology of cardiotonic drugs | C2 | Practical | OSPE |
| P-5 | Assessment of a Stain | Forensic Medicine | State the medicolegal importance of Biological specimens (Blood, Semen, Salvia, Vomitus, Breath, Urine, Hair). Briefly describe the method to Collect, preserve and dispatch various human body specimens | C2 C2 | Practical | OSPE |
| P-6 | Lipid profile and cardiac enzymes | Pathology | Enlist cardiac enzymesEnlist parameters for lipid profile | C1 C1 | Practical | OSPE |

| | 4th Week | | | | | | | |
|---------|---|--|---|--|---------------------|----------------------|--|--|
| Code no | Торіс | Discipline | At the end of the lecture student should be able to | C/P/A | Teaching strategies | Assessment tools | | |
| L-42 | Antiarrhythmic drugs III(class IV and class V) | Pharmacology | Describe mode of action, clinical uses and adverse effects of Class III and Class IV antiarrythmic drugs | C2 C2 | LGIS | MCQs SEQs VIVA | | |
| L-43 | Asphxia-I (Classification& Hanging) | Define Hanging , its types/classification and give causes of death of hangin Explain the medicolegal aspects of hanging Differentiate between ante mortem and post mortem hanging Differentiate between suicidal , homicidal and accidental hanging Enumerate its external and internal autopsy findings | | C1 C1 C2 C3 C2 C2 C2 | LGIS | MCQs SEQs VIVA | | |
| C-4 | Cardiomyopathies | Pathology | Formulate differential diagnosis of cardiomyopathy Describe pathogenesis of cardiomyopathies Classify Various types of cardiomyopathies Describe Consequences of cardiomyopathies Describe Morphological features of cardiomyopathies Demonstrate adequate communication skills in describing the clinical problem | C3 C2 C3 C2 C2 C2 A3 | CBL | MCQs SEQs VIVA | | |
| L-44 | Antiasthmatics II (Drug groups) | Pharmacology | Discuss the roles of corticosteroids in the treatment of bronchial asthma. C1 Discuss the role of ipratropium in asthma C2 Discuss the mechanism of action and adverse effects of leukotrine synthesis and receptor blockers used in asthma C2 Enlist drugs used in acute and chronic asthma C2 | C1 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA | | |
| L-45 | Asphxia –II (Strangulation) | Forensic Medicine | Define strangulation, its types/classification and give causes of death of strangulation. Explain the medico-legal aspects of strangulation. Differentiate between hanging and strangulation Differentiate between suicidal, homicidal and accidental strangulation | C1 C2 C2 C2 C2 C3 | LGIS | MCQs SEQs VIVA | | |
| C-5 | Anti asthamatic drugs | Pharmacology | • Rationalize the use of antiasthamatic drugs in specific clinical scanerio | C3 | CBL | MCQs SEQs | | |
| L-46 | Chronic bronchitis and emphysema | Pathology | Define COPD Enumerate diseases of COPD Differentiate b/w the pathophysiology of emphysema and chronic bronchitis. Correlate morphology of each type of emphysema with its pathogenesis | C1 C1 C3 C3 | LGIS | MCQs SEQs VIVA | | |

| L-47 | Antiasthmatics-II (Classification) | Pharmacology | Describe the mechanism of action & adverse effects of Beta 2 agonists used in asthma Describe the mechanism of action, actions & adverse effects of Methylxanthines Describe mechanism of action and adverse effects of Mast Cell Stabilizers | C2 C2 C1 | LGIS | MCQs SEQs |
|------|--|-------------------|--|----------------------------------|------|----------------------|
| L-48 | Approach to a patient with lymphedema | Surgery | Recall the main functions of the lymphatic system Recall the development of the lymphatic system. Enumerate the various causes of limb swelling. | C1 C1 C2 | | MCQs SEQs |
| | | | Briefly describe the etiology, clinical features and investigations of lymphedema. Outline management plan for lymphedema. | C2 C3 | | |
| L-49 | Asphxia – III (Suffocation) | Forensic Medicine | Define suffocation. Enlist different types of suffocation. Briefly explain the postmortem findings in death due to suffocation State the medico-legal importance of death from different types of suffocation | C1 C1 C2 C2 | LGIS | MCQs SEQs |
| L-50 | Asthma, COPD | Medicine | Describe pathophysiology of asthma and its clinical manifestations. Enlist predisposing factors of asthma. Describe diagnostic tests and management of asthma in step wise fashion. Define COPD and briefly describe pathophysiology of COPD. Enumerate risk factors for development of COPD. Outline investigations and management of COPD | C2 C1 C3 C2 C1 C3 | LGIS | MCQs SEQs |
| L-51 | Approach to a patient with cardiac diseases. (Cardiac surgery) | Surgery | Describe the cardiac diseases Ischemic heart disease, valvar heart diseases, congenital heart diseases, tumors of heart. Explain the basics of surgical treatment of different heart diseases like cardiac bypass, valve replacements etc. | C2 C2 | LGIS | MCQs SEQs |
| L-52 | Approach to a patient with Chest trauma and its management | Surgery | State the life threatening and potentially life threatening chest trauma (ATLS) Describe the treatment of chest trauma according to ATLS principles including chest intubation. | C2 C3 | LGIS | MCQs SEQs VIVA |
| S-1 | Anti tussive drugs | Pharmacology | Describe anti-tussive, mucolytics and expectorants Classify Anti-tussives Describe Pharmacodynamics of these drugs | C2 C2 C2 | SGD | PBQs |
| L-53 | Asphxia – IV (Drowning) | Forensic Medicine | Define drowning and Classify drowning. State the cause of death in different types of drowning Briefly explain the patho-physiology of wet drowning both in sea and fresh water. Describe the postmortem findings and their medico-legal importance. Differentiate between antemortem and postmortem drowning | C1 C2 C2 C2 C3 | LGIS | |

| S-5 | Tumors of CVS | Pathology | Describe epidemiology, pathogenesis, clinical feature and morphology of primary, metastatic and other tumors of heart. Describe epidemiology, pathogenesis, clinical feature and morphology of Benign Tumors and Tumor-Like Conditions of blood vessels. Describe epidemiology, pathogenesis, clinical feature and morphology of Intermediate-Grade (Borderline) Tumors of blood vessels. Describe epidemiology, pathogenesis, clinical feature and morphology of Malignant Tumors of blood vessels. | C2 C2 C2 C2 C2 | SGD | |
|------|-----------------------------------|-------------------|---|--|-----------|------|
| L-54 | Asthma & Bronchiectasis | Pathology | Enlist the types of asthma Describe etiology of asthma Describe the pathogenesis of asthma Enlist genetic associations of asthma Describe morphological changes in lungs in a patient with asthma Describe the pathogenesis of bronchiectasis Describe the gross and microscopic changes in bronchiectatic lung | C1 C2 C2 C1 C2 C2 C2 C2 C2 C2 | LGIS | |
| P-7 | P drug and prescription of CCF | Pharmacology | Rationalize the use of drugs in specific clinical scanerio | C3 | Practical | OSPE |
| P-8 | Asphyxiants | Forensic Medicine | Briefly describe the mechanism of action of asphyxial poison.(Carbomonoxide, Carbondioxide, Hydrogen sulphide) Mention the fatal dose, management & medico-legal importance of Asphyxial poison. Briefly explain the autopsy findings of a victim of Asphyxial poison. | C2 C2 C2 C2 C2 | Practical | OSPE |
| P-9 | MI and Rhematic heart disease | Pathology | Illustrate with help of diagram the different types of Vegetation in heart valves Interpret the morphological Changes in MI Demonstrate collaborative work in the group | P3 P3 A3 | Practical | OSPE |

| | | | 5th Week | | | |
|---------|----------------------------|-------------------|--|----------|---------------------|------------------|
| Code no | Topic | Discipline | At the end of the lecture student should be able to | C/P/A | Teaching strategies | Assessment tools |
| L-55 | Sexual Offences (Rape & | Forensic Medicine | • Define rape, intercourse, sodomy. | C1 | LGIS | MCQs |
| | Sodomy) | | • Explain laws relating to sexual offences. | C2 | | SEQs |
| | | | Assess the sexual offences and relate it to relevant Sections of Law (Zina and Hudood Ordina • | C3 | | VIVA |
| | | | • Differentiate between natural and unnatural sexual Offences. | C1 | | |
| | | | Define sodomy & Bestiality | C1 | | |
| | | | • Briefly explain the typical finding in active and passive agent of sodomy). | C2 | | |
| L-56 | Medico-legal aspects of | Forensic Medicine | Define pregnancy and describe forensic importance of delivery. | C1 | LGIS | MCQs |
| | Pregnancy ,Delivery and | | • Briefly explain the signs and symptoms of pregnancy. | C2 | | SEQs |
| | Abortion | | • Describe the autopsy findings in case of recent and remote delivery in living and dead body. | C3 | | VIVA |
| | | | • Enlist the types and methods of abortion. | C1 | | |
| | | | • Briefly explain the causes of death in abortion. | C2 | | |
| | | | • Assess the abortion and relate it to relevant Sections of Law & state its medico- | C3 | | |
| | | | legal aspects. | C2 | | |
| | | | • Briefly describe the autopsy findings in case of criminal abortion. | | | |
| L-57 | Medico-legal aspects of | Forensic Medicine | • Define infanticide, live born, dead born & still born. | C1 | LGIS | MCQs |
| | Infanticide | | • Briefly describe the method of assessing the age of fetus & define Hess's Rule. | C2 | | SEQs |
| | Child abuse Battered child | | • Differentiate between features of live and dead born. | C3 C2 | | VIVA |
| | & wife | | • Explain the autopsy findings in case of live and dead born. | C1 | | |
| | | | • Explain the magnitude of the problem related to child abuse. | C2 | | |
| | | | • Describe the phenomena of battered wife and related laws | C2 | | |
| | | | • Identify criminal and non-accidental violence or abuse to a newborn, infant or | C3 | | |
| | | | child | | | |
| L-58 | Custodial Torture | Forensic Medicine | Define Cusodial torture | C1 | LGIS | MCQs |
| | | | Briefly explain various types of custodial torture | C2 | | SEQs |
| | | | • Enlist the the types of injuries receive in custodial torture | C2 C3 | | VIVA |
| | | | • State the medicolegal importance of death in custody and custodial torture | CS | | |

23 | P a g e

| S-6 | Interstitial lung disease | Pathology | Define and classify interstitial lung diseases. | C3 | SGD | PBQs |
|------|---------------------------|-------------------|--|----------|------|----------|
| 5 0 | 6 | 85 | Differentiate between restrictive and obstructive lung diseases | C3 | ~ | |
| | | | Differentiate between fibrosing and granulomatous interstitial lung diseases. | C3 | | |
| | | | | C2 | | |
| | | | • Describe the Pathogenesis of idiopathic pulmonary fibrosis (IPF) | C2 C2 | | |
| | | | Describe the clinical features of restrictive lung disease | | | |
| L-59 | Bronchial Asthma | Family Medicine | • Discuss the risk factors for Asthma in our population | C2 | LGIS | MCQs |
| | | | • Explain the risk assessment for Asthma | C2 | | |
| | | | • Discuss the primary and secondary prevention of Asthma in a | C2 | | |
| | | | primary health setting | C3 | | |
| | | | • Identify the guidelines that should be followed in a patient with | | | |
| | | | Asthma | | | |
| L-60 | Pleural effusion | Medicine | Define pleural effusion. | C1 | LGIS | MCQs |
| | | | • Classify and explain different types of pleural effusion. | C2 | | SEQs |
| | | | Enlist causes and clinical features of pleural effusion. | C2 | | ~~~~~~ |
| | | | Outline investigations and treatment of pleural effusion. | C3 | | |
| | | | • | C2 | | |
| | | | Enlist indication of chest intubation in pleural effusion | 02 | | |
| S-7 | Acute Pulmonary | Pathology | • Classify pulmonary infections on basis of etiology and morphology. | C3 | SGD | PBQS |
| ~ . | infections | | Describe the pneumonia syndromes. | C3 | | C |
| | | | i i | C3 | | |
| | | | • Differentiate between the morphology of different types of pneumonia. | 0.5 | | |
| L-61 | Pneumonia | Paediatrics | Classify Pneumonia according to the WHO ARI protocol | C1 | LGIS | MCQs |
| | | | • Plan pertinent investigations, interpret and take appropriate action | C2 | | SEQs |
| | | | Assess complications | C2 | | VIVA |
| | | | - | C2 | | *1*/1 |
| | | | Manage Pneumonia and its complications | 02 | | |
| L-62 | Barbiturates & | Forensic Medicine | Briefly describe the mechanism of action of Barbiturates & Hypnotics | C2 | LGIS | MCQs |
| | Hypnotics | | Mention the fatal dose, management & medico-legal importance of Barbiturates | | | SEQs |
| | • • | | | C2 | | VIVA |
| | | | & Hypnotics | 02 | | |
| | | | • Briefly explain the autopsy findings of a victim of Barbiturates & Hypnotics | | | |
| | | | poisoning | C3 | | |
| S-8 | Chronic Pulmonary | Pathology | Describe chronic pneumonias. | C2 | SGD | PBQS |
| | infections | | • Describe epidemiology, pathogenesis, etiology and morphology of | | | |
| | | | Histoplasmosis, Coccidioidomycosis, and Blastomycosis. | C2 | | |
| | | | Describe Pneumonia in the Immunocompromised Host, Opportunistic Fungal | | | |
| | | | Infections and Pulmonary Disease in HIV. | C2 | | |
| L-63 | TUBERCULOSIS | Pathology | Enlist the risk factors for acquiring tuberculosis | C1 | LGIS | MCQs |
| | | 1 41101059 | 1 0 | C2 | 2010 | SEQs |
| | | | Describe pathophysiology of primary and secondary tuberculosis. | | | SEQS |
| | | | | (*) | | |
| | | | Describe the processes of formation of granulomas | C2 C2 | | |
| | | | • Differentiate between the morphology of lesions in primary and secondary | C2 C3 | | |
| | | | 1 0 | | | - |

| | | | Enumerate first and second line drugs for treatment of tuberculosis Describe mechanism of action uses and adverse effects of first line drugs used in tuberculosis | C2 C2 | | |
|------|--|-------------------|---|--|-----------|----------------------|
| C-6 | Squamous cell Carcinoma | Pathology | Classify lung tumors Describe the carcinogenic pathways of squamous cell carcinoma of lung Describe the morphology of squamous cell carcinoma of lung Correlate the clinical presentation of lung carcinoma with the stage of disease Interpret the clinical data of patient with lung carcinoma for the prognosis of the disease Demonstrate understanding of team work in diagnosing a patient with critical disease | C1 C2 C2 C3 P3 A2 | CBL | MCQs SEQs VIVA |
| L-64 | Croup | Paediatrics | State the etiology of croup Briefly explain the Clinical features and make differential diagnosis of stridor Enlist the X-Ray findings of CROUP Describe Treatment and Management plan of Croup | C1 C2 C1 C3 | LGIS | PBQS |
| L-65 | Anti TB drugs I & II | Pharmacology | Enlist 1st and 2nd line Anti TB Drugs Discuss their mechanism of action. Discuss their adverse effects and drug interaction Discuss different regimes for treatment of TB Describe drug interactions of isoniazid and Rifampicin | C1 C2 C2 C2 C2 C2 C2 | LGIS | MCQs SEQs VIVA |
| L-66 | Approach to benign Diseases of the Thorax | Surgery | Briefly describe different benign diseases of respiratory system of surgical importance like empyema, lung abscess, lobar collapse, destructive lung disease. Explain the basics of Surgical treatment of the benign diseases of thorax like chest intubation, VATS, thoracotomy. | C2 C3 | LGIS | MCQs SEQs VIVA |
| L-67 | Seminar on TB | Medicine | Recognize pathophysiology of Tuberculosis. Explain clinical features of Pulmonary and pulmonary Tuberculosis. Outline Investigations and management plan of Tuberculosis | C1 C2 C2 | LGIS | MCQs SEQs |
| P-10 | P drug and prescription of asthma and TB | Pharmacology | • Rationalize the use of antiasthamatic drugs in specific clinical scanerio | C3 | Practical | OSPE |
| P-11 | Assessment of a Rape victim | Forensic Medicine | Briefly describe the procedure of performing clinical l Assessment of victim and assailant in case of sexual assault. Explain the method of collection of specific specimens in sexual offences Write a required certification in case of diagnosed sexual assault | C2 C2 C2 C2 | Practical | OSPE |

| P-12 | Morphology of lung leisons | Pathology | Illustrate with the help of a diagram the morphology of emphysema Illustrate with the help of a diagram the morphology of granuloma Demonstrate positive attitude towards safe handling of laboratory specimens | Р3 Р3 А3 | Practical | OSPE | |
|------|-------------------------------|-----------|---|----------------|-----------|------|--|
|------|-------------------------------|-----------|---|----------------|-----------|------|--|

Family Medicine

| Lecture | Learning Objectives | Cognition level | Teaching Strategy | Assessment Strategy |
|------------------|--|-----------------|-------------------|---------------------|
| IHD/CCF | • Explain the management strategies of | C2 | LGIS | MCQs |
| | a patient with IHD and heart failure in | | | |
| | general practice including the | | | |
| | psychosocial impact of disease on | C2 | | |
| | patient and their families | | | |
| | • Describe the strategies for prevention | | | |
| | of IHD and CCF | | | |
| Bronchial Asthma | • Discuss the risk factors for Asthma in our population | C2 | LGIS | MCQs |
| | • Explain the risk assessment for | C2 | | |
| | Asthma Discuss the primary and secondary prevention of Asthma in a primary health setting | C2 | | |
| | • Identify the guidelines that should be followed in a patient with Asthma | C3 | | |

SDL Curriculum

(Self Directed Learning)

| | Week-1 | |
|---|--|---|
| | Pharmacology | |
| Topic | Learning Objectives | References |
| Role of α-2 agonists in clinical settings other than hypertension | Enlist the conditions in which α-2 agonists are used C1 Rationalize their use in these conditions C2 | Kaye AD, Chernobylsky DJ, Thakur P, Siddaiah H, Kaye RJ, Eng LK, Harbell MW, Lajaunie J, Cornett EM. Dexmedetomidine in enhanced recovery after surgery (ERAS) protocols for postoperative pain. Current pain and headache reports. 2020 May;24:1-3. Baller EB, Hogan CS, Fusunyan MA, Ivkovic A, Luccarelli JW, Madva E, Nisavic M, Praschan N, Quijije NV, Beach SR, Smith FA Neurocovid: pharmacological recommendations for delirium associated with COVID-19. Psychosomatics. 2020 Nov 1;61(6):585 96. Banas K, Sawchuk B. Clonidine as a treatment of behavioural disturbances in autism spectrum disorder: A systematic literature |
| | Dothology | review. Journal of the Canadian Academy of Child and Adolescent Psychiatry. 2020 May;29(2):110. |
| | Pathology | 1 |
| Disorders of veins & Lymphatics | Define heart failure C1 Describe the pathogenesis of right and left heart failure. C2 Describe compensatory responses of CVS for heart failure. C2 | |
| | Describe clinical features of right and left heart failure. C2 Describe morphology of different tissues in event of heart failure. C2 | |
| | Forensic Medicine | |

| Thanatology | • Briefly explain Scientific concepts regarding death, | https://www.merriam-webster.com/dictionary/thanatology https://pubmed.ncbi.nlm.nih.gov/22375350/ |
|-------------|--|---|
| | State Medico-legal aspect of Brain death Enlist Indicators of Death, medico-legal aspects of Sudden and unexpected deaths Define Cause, manner, mode and mechanisms of death | Parikh Text Book Of Forensic Medicine Principles of Forensic Medicine by Gautam Biswas |

| Week-2 | | | | |
|---|--|--|--|--|
| Pharmacology | | | | |
| Торіс | Learning Objectives | References | | |
| • Novel Anti anginal drug | Discuss the newer drugs used in management of different types of Angina C2 | Dutt HK, Pratik AH, Dhapola VS. Comparative Efficacy and Impact on Quality of Life with Add-on Therapy of Emerging Newer Anti Anginal Drugs in Stable Angina-A Meta-Analysis. Zhu H, Xu X, Fang X, Zheng J, Zhao Q, Chen T, Huang J. Effects of the antianginal drugs ranolazine, nicorandil, and ivabradine on coronary microvascular function in patients with nonobstructive coronary artery disease: a meta-analysis of randomized controlled trials. Clinical therapeutics. 2019 Oct | | |
| | Pathology | | | |
| • Heart failure | Define heart failure C1 Describe the pathogenesis of right and left heart failure. C2 Describe compensatory responses of CVS for heart failure. C2 Describe clinical features of right and left heart failure. C2 Describe morphology of different tissues in event of heart failure. C2 | | | |
| Forensic Medicine | | | | |
| Forensic Serology (Trace Evidence: Blood Semen & Saliva) | State Forensic importance of Biological specimens (Blood) Enumerate Methods of their collection, preservation and dispatch for common laboratory tests | https://www.sciencedirect.com/topics/medicine-and-dentistry/forensic- serology https://www.sjsu.edu/people/mary.juno/courses/1066/s7/ForensicSerology.pdf Parikh Text Book Of Forensic Medicine Principles of Forensic Medicine by Gautam Biswas | | |

| | Week-3 | |
|---|---|--|
| | Pharmacology | |
| Торіс | Learning Objectives | References |
| Current guidelines in the management of CCF | Explain current drug therapies used to treat heart failure C2 | Berliner D, Hänselmann A, Bauersachs J. The treatment of heart failure with reduced ejection fraction. Deutsches Ärzteblatt International. 2020 May;117(21):376. Authors/Task Force Members:, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. European journal of heart failure. 2022 Jan;24(1):4-131. |
| | Pathology | |
| Congenital heart disease | Define congenital heart diseases. C1 Enumerate common congenital heart diseases(CHD). C1 Describe pathogenesis of CHD. C2 Describe Left-to-Right Shunts, Right-to-Left Shunts and Obstructive Lesions. C2 | |
| | Forensic Medicine | e |
| • Asphxia | Detect the Anatomical, Physiological, Biochemical and Enlist Pathological signs of violent death; and of Mechanical, chemical and environmental asphyxia death and their medico legal implications. Recognize signs of violent death, mechanical, chemical and environmental asphyxia death | https://my.clevelandclinic.org/health/diseases/24725-asphyxiation https://www.webmd.com/first-aid/asphyxia-overview Parikh Text Book Of Forensic Medicine Principles of Forensic Medicine by Gautam Biswas |

| State their medico legal implications. | |
|--|--|
|--|--|

| | | | Week-4 | |
|---------------------------------------|---------------|----|--|---|
| | | | Pharmacology | |
| Topic | ; | | Learning Objectives | References |
| Management of immunocompromised pa | TB atients | in | • Discuss the use of anti TB drugs and antiretroviral drugs in immunocompromised states C2 | |
| | | | | Bastos ML, Melnychuk L, Campbell JR, Oxlade O, Menzies D. The latent tuberculosis cascade-of-care among people living with HIV: A systematic review and meta-analysis. PLoS Medicine. 2021 Sep 7;18(9):e1003703. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh Jr CR, Crane CM, Burgos M, LoBue P. Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. American Journal of Transplantation. 2020 Apr 1;20(4):1196-206. |
| | | | Pathology | |
| Pulmonary disea Vascular origin | ses of | | Describe epidemiology, etiology, pathogenesis, morphology, clinical features of Pulmonary Embolism, Hemorrhage, and Infarction. C2 Describe epidemiology, etiology, pathogenesis, morphology, clinical features of Pulmonary Hypertension. C2 Describe epidemiology, etiology, pathogenesis, morphology, clinical features of Diffuse Alveolar Hemorrhage Syndrome. C2 | |

| Forensic Medicine | | | |
|--|---|---|--|
| • SOCIAL CRIME : Sexual Offences, Abortion, Infanticide, Child abuse | Define Sexual Offences and Relevant Sections of Law (Zina and Hudood Ordinance) Enlist Natural and unnatural sexual offences Mention Criminal processes during delivery, their medico-legal aspects, Assessment procedure and reporting. Briefly explain Crime against New-Born, Infants and Child. Identify Infanticide and differentiation between live and dead born | https://ojp.gov/ncjrs/virtual-library/abstracts/offence-rape-islamic-law- pakistan https://reproductiverights.org/maps/provision/pakistans-abortion- provisions/ https://www.sciencedirect.com/topics/medicine-and-dentistry/infanticide Parikh Text Book Of Forensic Medicine Principles of Forensic Medicine by Gautam Biswas | |

Cardiovascular & Respiratory Module



Integrated Modular Curriculum



Cardiovascular & Respiratory Module – VI

Time Table 2023 Rawalpindi Medical University Duration Of Module: O6 Weeks Coordinator: Dr. Filza. Ali

Reviewed by: Module Committee Members of module committee

Co-Coordinators: Dr. Naila Batool & Dr. Raheel Baig

| Prof.Dr.Muhammad Umar | Chairman | Vice Chancellor RMU |
|-----------------------------|--|-------------------------------|
| Prof. Dr. Tahzeeb ul Hassan | Dean of Basic Sciences/Convener | Physiology Department |
| Prof. Dr Idrees Anwar | Dean & Member Curriculum Committee | Surgery Department |
| Dr. Asma Khan | Incharge 3 rd year Modular Curriculum | Pharmacology Department |
| Dr Omaima Asif | Overall Modular Coordinator | Pharmacology Department |
| Dr Attiya Munir | Focal Person | Pharmacology Department |
| Dr Mudassara | Focal Person | Pathology Department |
| Dr Gulzaib | Focal Person | Forensic Medicine Department |
| Dr Saima Ambreen | Focal Person | Medicine Department |
| Dr Huma Sabir | Focal Person | Surgery Department |
| Dr Afifa Kalsoom | Focal Person | Community Medicine Department |
| Dr Asad Shabbir | Focal Person | Pediatrics Department |

Approved by: Curriculum Committee

Documented By: Dr. Filza Ali

Prepared By: Dr. Filza Ali

| | 1 | | Time Table 3 rd Year MBBS | -CVS Module 2023 | (Week 1 | .) | | | |
|----------------------|--|--|--|--|--|--|---|--|--|
| DATE / DAY | 8:00 AM – 9:30 AM | 9:30 AM – 11:00 AM | 11:10am – 12:00pm | | 12:00 PM - | 02:00 PM | | | |
| | Clinical | l Clerkship | | Batch Practical | Topic of Practical | Teacher | Venue | | |
| Monday 2-11-23 | | | | Мос | lule Assessment of Haemotology, | Immunology and research(| written) | | |
| Tuesday 3-10-23 | | | Forensic Medicine* L-1 Thanatology- I (Introduction & Types of death) Immediate & Early changes of death) Dr. Romana Assot Prof Dr . Filza Ali Asst Prof Venue: lectute hall 1& 2 | | Batch Wise Viva Hae | matology Module | | | |
| Wednesday 4-10-23 | | | Forensic Medicine *L-2 Thanatology- II (Livor mortis & Rigor mortis) Dr. Romana Assot Prof Dr . Filza Ali Asst Prof Venue: lectute hall 1& 2 | Batch Wise Viva Haematology Module | | | | | |
| Thursday 5-10-23 | | | Community Medicine * L-3 Concept of environment & water Venue: lectute hall 1& 2 | | Batch Wise Viva Hae | ematology Module | | | |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am-10:15am | 10:15am - 11:00am | 10:15am - 11:00am 11:00am - 12:00pm | | | | |
| | Surgery * L-4 | Pathology * L-5 | Pharmacology* L-6 | Pathology * L-7 | CommunityMedicine*L-8 | | | | |
| Friday 6-10-23 | Approach to a patient with chronic Peripheral arterial Disease Dr. Aurangzeb AP, SU II, BBH Dr. Iqbal AP, SU II, BBH Venue: lect hall 1& 2 | Artherosclerosis Pathogenesis and morphology Teacher Name: Prof Mobina Ahsan Dodhy Dr Wafa Venue: lecture hall 1& 2 | Anti-hypertensive I (Introduction and classification) Dr. ZuneraAssist prof Dr. Asma Khan associate prof Venue: lecture hall 1& 2 | Consequences of Atherosclerosis Prof Mobina Ahsan Dodhy Dr Wafa Venue: lecture hall 1& 2 | Water distribution, Conservation and purification Dr. Nargis Sr Demo Dr. Maimoona Sr. Demo Venue: lecture hall 1& 2 | | | | |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am – 10:30am | 10:30 AM – 11:00 am | 11:00am – 12:00pm | 12:00:pm - 01:00pm | 01:00pm – 02:pm | | |
| | Medicine *L-9 | Obstetrics *L 10 | Pharmacology *L-11 | BREAK | Community Medicine*L-12 | Pathology ** S-1 | Community Medicine * I 13 | | |
| Saturday 7-10-23 | Hypertension Dr. Abrar Akbar Dr.Maryam Venue lecture hall 1& 2 | Hypertensive disorders in pregnancy PIH, Preeclampsia Dr.Ruqhia Sr DHQ Dr Asma khan Sr BBH Venue: lecture hall 1 & 2 | Antihypertensive II (ACE inhibitors and ARBs) Dr Attiya MunirAsst Prof Dr Sobia Assistant Prof Venue: lecture hall 1 & 2 | | Air and Ventilation (control of air pollution) Dr. Gulmehar AP Dr. Imran AP Venue: lecture hall 1& 2 | Hypertensive Heart Disease Dr. Muddassira,Dr. Tayyaba Dr. Fatima , Dr. Aasiya | Air and Ventilation (global warming.) Dr. Gulmehar AP Dr. Imran AP Venue: lecture hall 1& 2 | | |

Tentative Time Table 3rd Year MBBS – CVS Module 2023 (Week 2)

| DATE / DAY | 8:00 AM - 9:30 AM | | $\frac{\text{DIE S} \text{YEAT IVIBBS} - \text{CVS}}{11:10\text{am} - 12:00\text{pm}}$ | | 2023 (WOOK 2) | 12:00 PM - 02 | 2:00 PM | | |
|----------------------|--|---|--|---|--|--|--------------------------------|-------------|---|
| | | Clinical Clerkship | Pharmacology* L-14 | Batch | Practical | Topic of Pr | actical | Teacher | Venue: |
| Monday | | | Antihypertensives III (Vasodilators) | А | Pharmacology P1 | P drug and prescription of | HTN | Dr Arsheen | Pharma lab |
| 9-10-23 | | | Dr Attiya Assistant prof | В | Forensic Medicine | 2 Cardiac Poisons | | Dr. Gulzaib | Forensic lab |
| | - | | Dr Sobia Assistant prof Venue: lecture hall 1 & 2 | С | Pathology P3 | Morphology of vascular le | sions | Dr Nida | Patho lab |
| | | | Pharmacology *L-15 | Batch | Practical | Topic of Practical | | ſ | I |
| | | | Antihypertensives IV (Ca | В | Pharmacology P1 | P drug and prescription of | HTN | Dr Arsheen | Pharma lab |
| Tuesday | | | Channel Blockers) | С | Forensic Medicine | P2 Cardiac Poisons | | Dr. Gulzaib | Forensic lab |
| 10-10-23 | | | Dr. ZuneraAssist Prof Dr. Asma Khan Assoct Prof | А | Pathology P3 | Morphology of vascular le | sions | Dr Nida | Patho lab |
| | | | Community Medicine*L-16 | Batch | Practical | Topic of Practical | | | |
| Wednesday | | | Prevention of Radiation Hazards | С | Pharmacology P1 | P drug and prescription of | HTN | Dr Arsheen | Pharma lab |
| 11-10-23 | | | Dr. Imrana Sr Demo Dr. Abdulquddoos Demo | А | Forensic Medicine | P2 Cardiac Poisons | | Dr. Gulzaib | Forensic lab |
| | | | Venue: lecture hall 1 & 2 | В | Pathology P3 | Morphology of vascular le | sions | Dr Nida | Patho lab |
| | | | 11:10am – 12:00pm | 12:00pm-1:00pm | | | | 1:00 pm | – 2:00pm |
| | | | Pharmacology* L-17 | Forensic 1 | ensic Medicine* L-18 | | Patholo | ogy ** S-2 | |
| Thursday 12-10-23 | | | Antianginal I Dr Asma Assot Prof, Dr SobiaaAssist Prof Venue: lecture hall 1& 2 | Dr. Roma Dr. Shahi | gy- III nges of Death Putrefac na Assot Prof da Sr.Demo cture hall 1 & 2 | ction) | Dr. Mudda Tayyaba | a tuz Zahra | |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am – 10:15am | 10:15am - | - 11:00am | 11:00am – 12:00pm | | | |
| | Medicine *L-19 | Pharmacology *L-20 | Pharmacology ***C-1 | Quran Clas | ss * L-21 | Pathology** S-3 | 1 | | |
| Friday 13-10-23 | Ischemic Heart Disease Dr. Abrar Akbar Dr.Maryam Venue: lecture hall 1 & 2 | Antianginal II Dr Asma Assot Prof, Dr SobiaaAssist Prof Venue: lecture hall 1& 2 | Diuretics Dr RubinaSRDemosnstrtor, Dr Arsheen, Demosnstrtor Dr HaseebaSRDemosnstrtor, Dr OmaimaDemosnstrtor | Venue:CPC Ischemie Dr. Muc Tayyaba Dr. Fatin | | schemic Heart Disease Dr. Muddassira Dr. Fayyaba Dr. Fatima tuz Zahra Dr. Aasiya2 | | | |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am – 10:30am | 10:30 | AM – 11:00 am | 11:00am – 12:00pm | 12:00:pm | n – 01:00pm | 01:00pm-02:pm |
| Cotonal | Pathology *** C-2 | Peads* L-22 | Surgery * L-23 | | BREAK | Forensic Medicine * L-24 | Peads * I | L-25 | Pharmacology* L-26 |
| Saturday 14-10-23 | Vascuilitis Dr SyedaAyesha Dr. Fariha Sardar Dr Iqbal haider Dr. Unaiza | Cyanotic congenital heart disease Dr Hafeez SR HFH, Dr Maria SR HFH Venue: lecture hall 1 & 2 | Approach to a patient with Gangrene and Amputations Dr. Nazan SR, SU II, BBH Dr. Yasmeen SR, SU I, BBH Venue: lecture hall 1 & 2 | | 1 1 | Thanatology- IV Adipocere, Mummification Estimation of time since death Dr. Romana Assot Prof Dr. Shahida Sr.Demo Venue: lecture hall 1 & 2 | Dr Jawar Dr Faiza SR BBH | | CCF I (Introduction classification Dr Attiya Assist Prof, Dr Zunera Assist Prof |

Tentative Time Table 3rd Year MBBS – CVS Module 2023

(Week3)

| DATE / DAY | 8:00 AM - 9:30 AM | 9:30 AM – 11:00 AM | $\frac{11:10 \text{ am} - 12:00 \text{ pm}}{11:10 \text{ am} - 12:00 \text{ pm}}$ | ~ 1.1040 | | (weeks) 12:00 PM - 02: | :00 PM | | |
|----------------------|--|---|---|------------------------|--|--|---|----------------------------|---|
| | | Clinical Clerkship | Pathology ** S-4 | Batch | Practical | Topic of Practical | | Teacher | Venue |
| March | | • | Aneurysms & Dissection Dr. Muddassira | А | Pharmacology | P4 P drug and prescription of an | gina | Dr. uzma | Pharma lab |
| Monday | | | Dr. Tayyaba | В | Forensic medi | cine P5 Assessment of a Stain | | Dr. Shahrukh | Forensic lab |
| 16-10-23 | | | Dr. Fatima tuz Zahra Dr. Aasiya | С | Patholog y P | 6 Lipid profile and cardiac en | nzymes | Dr Saeed | Patho lab |
| | - | | Medicine* L-27 | Batch | Practical | Topic of Practi | cal | | |
| | | | Rheumatic fever Dr. Abrar Akbar | В | Pharmacology | P4 P drug and prescription of an | ngina | Dr. uzma | Pharma lab |
| Tuesday 17-10-23 | | | Dr.Maryam Venue: lecture hall 1 & 22 | С | Forensic medie P5 | cine Assessment of a St | ain | Dr. Shahrukh | Forensic lab |
| 17-10-25 | | | | А | Pathology P | 5 Lipid profile and cardiac en | nzymes | Dr Saeed | Patho lab |
| |] | | Forensic Medicine * L-28 | Batch | Tumors of CV | S Topic of Prac | etical | | |
| Wednesday | | | Forensic Serology Trace Evidence | С | Pharmacology | P4 P drug and prescription of an | ngina | Dr. uzma | Pharma lab |
| 18-10-23 | | | Blood, Semen & Saliva Dr. Romana Malik Assoct Prof | А | Forensic Medi | cine P5 Assessment of a Stain | | Dr. Shahrukh | Forensic lab |
| | | | Dr . Filza Ali Asst Prof Venue: lecture hall 1 & 2 | В | Pathology P6 | Lipid profile and cardiac en | nzymes | Dr Saeed | Patho lab |
| | - | | 11:10am-12:00pm | | | 00pm-1:00pm | | | m – 2:00pm |
| Thursday 19-10-23 | | | Pathology * L-29 Pathogenesis of Rheumatic Fever Morphological changes in Rheumatic Heart Disease Prof Mobina Ahsan Dodhy Dr Wafa Venue: lect hall 1& 22 | related dr Zunera A | Pharmacolo Digoxin and ugs): Dr Attiya, A sssistant Prof ecture hall 1 & 2 | Assistant Prof Dr | Dr. Abra Dr.Mary | e endocarditis ar Akbar | icine *L-31 2 |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am – 10:15am | | n - 11:00am | 11:00am-12:00pm | | | |
| Friday 20-10-23 | Medicine *L-32 Valvular heart disease Dr. Aimen SR HFH | Paediatric* L-33 Rheumatic fever Dr Sonia SR HFH Dr Amel Hechem SB HEH | | IHD/CCF Dr Saadia I | Khan HOD | Pathology * L-36 Infective Endocarditis Prof Dr. Mobina Dodhy, | | | |
| | , Dr. Ibrar AP HFH lecture hall 1&2 | Dr Amal Hasham SR HFH Venue: lecture hall 1 & 2 | khan Assoct Prof Venue: lecture hall 1& | Venue: lect | ure hall 1 & 2 | Dr Wafa Venue: lecture hall 1 & 2 | | | |
| Saturday | 08:00am - 08:45am | 08:45am – 09:30am | 09:30am – 10:30am | 10:30 AN | 1 – 11:00 am | 11:00am – 12:00pm | - | m – 01:00pm | 01:00pm-02:pm |
| 21-10-23 | Pathology***C-3 Myocarditis and pericarditis Dr Fatima .Dr Nida, Dr. Abid, Dr. Saeed | Surgery* L-37 Approach to a patient with DVT and varicose veins Dr. Amina SR, SU II, HFH Dr. Omer Qaiser SR, Surgery, DHQ, | Paediatric * L-38 Childhood Asthma Dr.Maryam SR HFH Dr,Irum SR HFH Venue: lecture hall 1 & 2 | | Break | Pharmacology * L-39 Antiarrhythmic drugs I (Introduction to normal rhythm and classification) Dr Asma Assot Prof , Dr SobiaaAssist Prof | Antiarryt (class I at Dr Asma Dr Sobia | rof Venue: | Obstetrics *L-41 Gestational diabetesmellitus Dr Ruqhia Sr DHQ Dr Asma khan Sr BBH Venue: lecture hall 1 & |

38 | Page

| Tentative Time Table 3 rd Year MBBS – CVS Module 2023 |
|--|
| Tentative Time Table 5 Teat MDD5 C V5 Module 2025 |

(Week 4)

| DATE / DAY | 8:00 AM - 9:30 AM | 9:30 AM – 11:00 AM | 11:10am – 12:00pm | | | 12:00 PM - 02 PM | :00 | | |
|----------------------|--|--|--|-----------------------------------|--|--|--------------------|--|---|
| | Clinical | l Clerkship | Pharmacology* L-42 | Batch | Practical | Topic of Practical | | Teacher | Venue |
| | | 1 | Antiarrhythmic drugs III(class | А | Pharmacology P7 | P drug and prescription of C | CCF | Dr Haseeba | Pharma lab |
| Monday | | | IV and class V) Dr Asma associate prof | В | Forensic medicine P8 | Asphyxiants | | Dr. Naila | DHQ |
| 23-10-23 | | | Dr Sobia assistant prof Venue: lecture hall 1 & 2 | С | Pathology P9 | MI and Rheumatic heart dis | ease | Dr Ali | Patho lab |
| | | | Forensic Medicine * L-43 | Batch | Practical | Topic of P | ractical | | |
| | | | Asphxia-I (Classification& Hanging) Dr. Romana | В | Pharmacology P7 | P drug and prescription of C | CCF | Dr Haseeba | Pharma lab |
| Tuesday | | | Assot Prof Dr. Filza Ali Asst Prof Venue: lecture hall 1 & 2 | С | Forensic Medicine P8 | Asphyxiants | | Dr. Naila | DHQ |
| 24-10-23 | | | Venue: lecture hall 1 & 2 | А | Pathology P9 | MI and Rheumatic heart dis | ease | Dr Ali | Patho lab |
| | | | Pathology ***C-4 | Batch | Practical | 1 | of Practica | | |
| | | | Cardiomyopathies | С | Pharmacology P7 | P drug and prescription of C | CCF | Dr Haseeba | Pharma lab |
| Wednesda | | | Dr. Sayed Ayesha Dr. Fariha | А | Forensic Medicine P8 | Asphyxiants | | Dr. Naila | DHQ |
| У | | | Dr Iqbal haider Dr. Unaiza | В | Pathology P9 | MI and Rhematic heart dise | ase | Dr Ali | Patho lab |
| 25-10-23 | | | 11:10am-12:00pm | | 12:00pm | | | 1:00 pm - | - 2:00pm |
| | | | Pharmacology * L-44 | Forensic | Medicine * L-45 | | Pharma | acology***C-5 | ···· I |
| Thursday 26-10-23 | | | Antiasthmatics-I (Drug groups) Dr Asma assoc prof , Dr Sobia assist prof | Dr. Ror Dr. Filza Venue: le | –II (Strangulation) nana Assot Prof a Ali Asst Prof ecture hall 1 & 2 | | Dr Rut Dr Has | sthamatic drugs bina, Sr Demo , Dr seeba Sr Demo,,Dr 5: See Anexure | |
| | 08:00am - 08:45am | 08:45am-09:30am | 09:30am – 10:15am | 10:15an | n - 11:00am | 11:00am-12:00pm | | | |
| | Pathology * L-46 | Pharmacology * L-47 | Surgery* L -48 | Forensic 1 | Medicine)* L-49 | Medicine* L-50 | | | |
| Friday 27-10-23 | Chronic bronchitis and emphysema Prof Dr.Mobina Ahsan Dodhy , Dr Wafa Lecture 1&2 | Antiasthmatics -II (Classification) Dr Asma Assot Prof, Dr Sobia Assist Prof Venue: lecture hall 1& 2 | Approach to a patient with lymphedema Dr. Waqas Hassan SR,HFH Dr. Samra , Sr, DHQ Venue: lect hall 1&2 | Dr. Ror Dr. Filz | – III (Suffocation) nana Assot Prof za Ali Asst Prof lecture hall 1 & 2 | Asthma, COPD Dr. Abrar Akbar Dr.Maryam Venue: lec hall 1 & 2 | | | |
| | 08:00am - 08:45am | 08:45am-09:30am | | 10:30 A | M – 11:00 am | 11:00am-12:00pm | 12:00:p | pm – 01:00pm | 01:00pm-02:pm |
| Saturday | Surgery * L-51 | Surgery * L-52 | Pharmacology **S-1 | | BREAK | Forensic medicine * L-53 | Patholo | ogy** S-5 | Pathology*L-54 |
| 2010 20 | Approach to a patient with cardiac diseases. (Cardiac surgery) Dr. Qasim SR, S U II, HFH Dr. Asifa Diyan SR, Su I, BBH Venue: lecture hall 1&2 | Approach to a patient with Chest trauma and its management Dr. Huma Sabir Khan AP, SU II, BBH Dr. Rahat AP, Surgery, BBH Venue: lecture hall 1,2 | Anti tussive drugs Dr RubinaSr semonstrator DrArsheen, Demonsrater Dr HaseebaSr demonstrator ,Dr Omaima demonstrator Venue: See Anexure | | | Asphxia – IV (Drowning) Dr. Romana Assot Prof Dr. Filza Ali Asst Prof Venue: lecture hall 1 & 2 | Dr. Muc Dr. Tay | ma tuz Zahra | Asthma & Bronchiectasis Pro Mobina Ahsan Dodhy , Dr Wafa Lecture 1&2 hall1&2 |

Tentative Time Table 3rd Year MBBS – CVS Module 2023

| | | Tentative T | Time Table 3 rd Year MBBS - | CVS | Module 2023 | (Week5) | | | |
|----------------------|---|---|---|-----------|---|--|---|-------------------------|--|
| DATE / DAY | 8:00 AM – 9:30 AM | 9:30 AM – 11:00 AM | 11:10am – 12:00pm | | | 12:00 PM - 02:00 PM | | | |
| | | linical erkship | Forensic medicine * L-55 | Batch | Practical | Topic of Practical | | | |
| Monday | | L | Sexual Offences (Rape & Sodomy) | | Pharmacology P10 | P drug and prescription of asth and TB | nma Dr | Omiama | Pharma lab |
| 30-10-23 | | | Dr.Filza Ali Asst Prof Dr. Gulzaib Sr Demo | В | Forensic Medicine P11 | Assessment of a Rape victim | | Raheel | DHQ |
| | | | Venue: lecture hall 1, 2 | С | Pathology P12 | Morphology of lung leisons | Dr | Abid | Patho lab |
| | - | | Forensic Medicine * L-56 | Batch | Practical | Topic of Practical | | | · |
| | | | Medico-legal aspects of Pregnancy ,Delivery and Abortion | В | Pharmacology P10 | P drug and prescription of asth and TB | nma Dr | Omiama | Pharma lab |
| Tuesday | | | Dr. Romana Assoct Prof Dr.Filza Ali Asst Prof | С | Forensic Medicine P11 | Assessment of a Rape victim | Dr. I | Raheel | DHQ |
| 31-10-23 | | | Venue: lecture hall 1, 2 | А | Pathology P12 | Morphology of lung leisons | Dr | Abid | Patho lab |
| | 1 | | Forensic Medicine *L-57 | Batch | Practical | Topic of Practical | • | | |
| | | | Medico-legal aspects of Infanticide child abuse Battered child & wife | | Pharmacology P10 | P drug and prescription of asth and TB | | Omiama | Pharma lab |
| Wednesday 1-11-23 | | | Dr. Romana Assoct Prof Dr. Shahrukh Sr. Demo | А | Forensic Medicine P11 | Assessment of a Rape victin | n Dr. I | Raheel | DHQ |
| 1-11-25 | | | Venue: lecture hall 1, 2 | В | Pathology P12 | Morphology of lung leisons | Dr | Abid | Patho lab |
| | - | | 11:10am – 12:00pm | | 12:00pm- | 1:00pm | | 1:00 pm- | - 2:00pm |
| | | | Forensic Medicine* L-58 | Pathol | ogy** S-6 | | Family Medi | - | 1 |
| Thursday | | | Custodial Torture | | tial lung disease | | <u> </u> | | |
| | | | | | ldassira Dr. Tayyaba | | Bronch | nial Asthma | |
| 2-11-23 | | | Dr.Filza Ali Asst Prof | Dr. Fatiı | na tuz Zahra Dr. Aasiya ect hall 1 & 2 | | Dr Saadia K Venue: lect l | Khan HOD | |
| Friday | 08:00am - 08:45am | 08:45am - 09:30am | 09:30am – 10:15am | | m - 11:00am | 11:00am – 12:00pm | | | |
| | Medicine* L-60 | Pathology** S-7 | Paediatrics *L-61 | Forens | ic Medicine*L-62 | Pathology** S-8 | | | |
| 3-11-23 | Pleural effusion | Acute Pulmonary infections | Pneumonia | | ates & Hypnotics | Chronic Pulmonary | | | |
| | Dr. Abrar Akbar/ Dr. | Dr. Muddassira | Dr Uzma SR BBH | Dr. Sh | ahida Sr.Demo | infections | | | |
| | Maryam | Dr. Tayyaba Dr. Aasiya | Dr.Afrah SR BBH | | ila Sr Demo | Dr. MuddassiraDr. Tayyaba | | | |
| | | Dr. Fatima tuz Zahra | Venue: lecture hall 1 & 2 | | lecture hall 1, 2 | Dr. Fatima , Dr. Aasiya | | | |
| Saturday | 08:00am - 08:45am | 08:45am - 09:30am | 09:30am – 10:30am | 10:30 / | AM – 11:00 am | - | 12:00:pm – | - | 01:00pm-02:pm |
| 4-11-23 | Pathology *L-63 | Pathology ***C-6 | Paediatrics *L-64 | | BREAK | Pharmacology *L-65 | Surgery *L- | 66 | Medicine *L-67 |
| SEMINAR | TUBERCULOSIS Prof Dr. Naeem Venue: CPC Hall | Squamous cell Carcinoma Dr Fatima ,Dr Nida, Dr. Abid Dr. Saeed Venue: CPC Hall | Croup Dr Saima Dr Mamona Qudrat Venue: lecture hall 1& 2 | | | Dr AttiyaAssistant prof, Dr Zunera assistant prof Venue: lecture hall 1,2 | Approach to b Diseases of th Dr. ZafarAP, Dr. AtifAP,H Venue: lectu | ne Thorax DHQ IFH | Seminar on TB Dr. Abrar Akbar/ Dr.Maryam Venue: lecture hall 1 &2 |

| Ttentative Time Table 3 rd | Year MBBS – CVS Module 2023 (Week 6) |
|---------------------------------------|--------------------------------------|
|---------------------------------------|--------------------------------------|

| DATE / DAY | 8:00 AM – 9:30 AM | 9:30 AM – 11:00 AM | 11:10am – 12:00pm | 12:00 PM - 02:00 PM |
|----------------------|-------------------|--------------------|-------------------|--|
| DATE/DAT | Clinical Clerk | ship | | |
| Monday 6-11-23 | | | | Block- III (Haematology & CVS Module) Theory Exam |
| Tuesday 7-11-23 | | | | BLOCK - III OSPE & VIVA |
| Wednesday 8-11-23 | | | | BLOCK - III OSPE & VIVA |
| Thursday 9-11-23 | | | | BLOCK - III OSPE & VIVA |
| Friday | | | PREP | P-LEAVE |

Teaching Hours

| SR No. | Disciplines | LGIS | SGD | CBL | SDL | Seminar | Hours |
|-----------|--------------------|------|-----|-----|-----|---------|-------|
| 1. | Pharmacology | 13 | 1 | 2 | 0 | 2 | 18 |
| 2. | Pathology | 06 | 08 | 4 | 0 | 1 | 19 |
| 3. | Forensic Medicine | 14 | 0 | 0 | 0 | 0 | 14 |
| 4. | Community Medicine | 5 | 0 | 0 | 0 | 0 | 5 |
| 5. | Medicine | 8 | 0 | 0 | 0 | 1 | 9 |
| 6. | Paeds | 5 | 0 | 0 | 0 | 1 | 6 |
| 7. | Surgery | 6 | 0 | 0 | 0 | 1 | 7 |
| 8. | obstetrics | 2 | 0 | 0 | 0 | 0 | 2 |
| | Total | | | | | | |

| Disciplines | Practical hours |
|-------------------|-----------------|
| Pharmacology | 2x4= 8 |
| Pathology | 2x4 =8 |
| Forensic Medicine | 2x4 = 8 |

*

LGIS (L)

➤ SGD (S) **

► CBL (C) ***'

➢ SDL (SL) ****

♦ For CBL/SGDs, whole class will be divided into 04 batches

Batch: A = Lecture Hall 01 (starting from batch A1 to A3) Batch: C = Lecture Hall 06 (starting from batch B3, B4, B5, C1) Batch: B = Lecture Hall 02 (starting from batch A4, A5, B1,B2) Batch: D = Pharmacy Lab (starting from batch C2 to C5)

The batch distribution & venues for whole year are fixed with no change except for extra ordinary situation.

Venues for Academic Sessions 3rd Year MBBS

• Large Group Interactive Sessions (LGIS)

Odd roll numbers: Lecture Hall 01

Even roll numbers: Lecture Hall 02

• <u>Small Group Discussion (SGD) /Case Based Learning (CBL)</u>

Lecture Hall 01 Lecture Hall 02 Lecture Hall 06 Pharmacy Lab In case of non-availability of these venues, CPC will be used for two batches

The batch distribution & venues for whole year are fixed with no change except for extra ordinary situations.

Rawalpindi Medical University Rawalpindi

Date: 31st July, 2023 by DME,, New Teaching Block


Section IV

- Assessment Policies

Contents

- Assessment planTypes of Assessment:
- Modular Assessments
- Block Assessment ٠
- Table 4: Assessment Frequency & Time in Foundation Module

Date: 18th February, 2023 by DME, New Teaching Block



Assessment plan

University has followed the guidelines of Pakistan Medical and Dental Council for assessment. Assessment is conducted at the mid modular, modular and block levels.

Types of Assessment:

The assessment is formative and summative.

Formative Assessment

Formative assessment is taken at modular $(2/3^{rd})$ of the module is complete) level through MS Teams. Tool for this assessment is best choice questions and all subjects are given the share according to their hour percentage.

Summative Assessment:

Summative assessment is taken at the mid modular (LMS Based), modular and block levels.

Modular Assessment

Theory Paper

There is a module Assessment at the end of first module of each block. The content of the whole teaching of the module are tested in this Assessment. It consists of paper with objective type questions and structured essay questions. The distribution of the questions is based on the Table of Specifications of the module. (Annexure I attached)

Viva Voce:

Structured table viva voce is conducted including the practical content of the module.

Block Assessment

On completion of a block which consists of two modules, there is a block Assessment which consists of one theory paper and a structured viva with OSPE. Theory Paper

There is one written paper for each subject. The paper consists of objective type questions and structured essay questions. The distribution of the questions is based on the Table of Specifications of the module.

Block OSPE

This covers the practical content of whole block.

Table 4-Assessment Frequency & Time in Foundation Module II

| Block | | Module – 2 | | Total Assessment | s Time | No. of Assessments | | |
|---------|------|---|-----------|------------------------------|------------|--------------------|-------------|-------------|
| | Sr # | Foundation Module Components | | Assessment | Summative | Formative | | |
| | | | | Time | Assessment | Assessment | | |
| | | | | | Time | Time | | |
| | | | | | | | | |
| | 1 | Mid Module Assessments LMS based | Summative | 30 Minutes | | 30 Minutes | 1 Formative | 5 Summative |
| | | (Pharmacology, Pathology, Forensic | | | | | | |
| | | Medicine, Medicine, Surgery, Peads, | | | | | | |
| | | Family Medicine, Research) | | | | | | |
| ζ-Ι | 2 | Topics of SDL Assessment on MS Team | Formative | 10 Minutes (Every Friday) | | | | |
| Block-I | 3 | End Module Assessments (SEQ & MCQs Based) | Summative | 6 Hours | | | | |
| | 4 | Pharmacology Structured and Clinically Oriented Viva | Summative | 10 Minutes | 7 hours | | | |
| | 5. | Forensic Medicine Structured and Clinically oriented Viva | Summative | 10 Minutes | | | | |
| | 5 | Pathology Structured & Clinically oriented Viva | Summative | 10 Minutes | | | | |

Learning Resources

| Subject | Resources |
|------------------------|---|
| | 1. |
| | |
| Pathology/Microbiology | Text Books |
| | 1. Robbins & Cotran, Pathologic Basis of Disease, 10 th edition. |
| | 2. Rapid Review Pathology, 5 th edition by Edward F. Goljan MD. |
| | 3. http://library.med.utah.edu/WebPath/webpath.html |
| Pharmacology | Text Books |
| | 1. Basic and Clinical Pharmacology by Bertram Z. Katzung 15th Edition |
| | 2. Goodman and Gillmans The Pharmacological basics of Therapeutics, 13th Edition |
| Forensic Medicine | Text Books |
| | 1. Parikh Text Book of Medical Jurisprudence Forensic Medicine & Toxicology Edition 9 |
| Medicine | Text Books |
| | Davidsons Textbook of Medicine |
| Surgery | Text Books |
| | Balley & Love textbook of surgery |
| Research | Digital library |
| | |

SECTION VI

Table of Specification (TOS) For CVS & Resp Module Assessment for 3rd Year MBBS

| Sr. # | Discipline | No. of MCQs | No. of MCQs according to cognitive domain | | | No. of SEQs (%) | | No. of SEQs according to | | | Viva voce | OSPE Marks | Total Marks |
|-------|-------------------|----------------|--|----|----|--------------------|-------|-----------------------------|-----------|---------|--------------|---------------|----------------|
| | | (%) | | | | No. of | Marks | cogr | nitive do | main | | | |
| | | | C1 | C2 | C3 | items | | C1 | C2 | C3 | | | |
| 1. | Pharmacology | 15 | 2 | 9 | 4 | 7 | 35 | 2 | 4 | 1 | 30 | 20 | 100 |
| 2. | Forensic Medicine | 15 | 4 | 9 | 3 | 5 | 25 | 2 | 2 | 1 | 10 | 0 | 50 |
| 3. | Pathology | 25 | 2 | 5 | 3 | 7 | 35 | 2 | 4 | 1 | 40 | 10 | 100 |
| 4. | Family Medicine | 5 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| 6. | Research | 5 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| 7. | Medicine | 5 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| 8. | Surgery | 5 | 1 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| 9. | Peads | 5 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| | | | | | | | | | Gran | d Total | | 275 | |

Annexure I

(Sample MCQ & SEQ papers with analysis)

Sample of MCQs Paper

Detailed Analysis of Sample of MCQs Paper

| Level of Cognition | Question No | Total | Percentage |
|--------------------|--|-------|------------|
| C1 | 4, 13, 19, 26, 27, 36, 47, 51, 54 | 09 | 16% |
| C2 | 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 17, 18, 20, 22, 23, 25, 28, 29, 30, 32, 33, 34, 40, 41, 42, 43, 45, 46, 48, 49, 50, 52, 53, 55 | 38 | 69% |
| C3 | 21, 24, 31, 35, 37, 38, 39, 44 | 08 | 15% |

| Type of Integration | Question No | Total | Percentage |
|---------------------------|---|-------|------------|
| Core | 1, 3, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16, 19, 26, 27, 28, 29, 30, 32, 33, 34, 36, 37, 39, 40, 41, 42, 43, 46, 47, 48, 49, 51, 53 | 34 | 62% |
| Horizontal | 4, 17, 24, 38, 52 | 05 | 9% |
| Vertical | 2, 18, 21, 25, 31, 44, 50 | 07 | 13% |
| Spiral | 5, 8, 20, 23, 45, 54 | 06 | 11% |
| Research & medical ethics | 22, 35, 55 | 03 | 5% |

Matsura 15/11/22

Prof. Mobina Ahsan Dodhy Chairperson Pathology Department Rawalpindi Medical University

vz Assistant Director

Department of Medical Education Rawalpindi Medical University

Vice Chancelon 9/12/12 Rawalpindi Medical University Rawalpindi

OPPO A54 · ©love ya 2023/02/18 10:44

Date: 18th

Sample Paper of SEQs physician is suspecting Hepatitis B in a patient in the ward. The laboratory performs a rapid kit test but the 000 physician has asked them to perform ELISA for confirmation as it is based on specific antigen antibody reaction Q7. A 45 years female presented with painless diffuse enlargement of thyroid gland. Her thyroid function tes 03 3 creatinine in 10-month time period despite immunomodulatory drugs. He states that he was alright and all his lab results were normal for few months after the 02 02 01 repeated infections. Physical examination shows scattered bruises on body. Her laboratory investigations reveals Hb 7.3 g/dL 02 02 01 2.5 30 years female with history of easy bruising and increased menstrual flow was evaluated for a bleeding 1.5 \times $10^{\circ}/L$) and an elevated lactate dehydrogenase level. A complete spectrum of myeloid cells is seen in the peripheral 2.5 Q2. A 65-years man presents to clinic with fatigue, night sweats, and lethargy of 6 months duration. He tells you that he has experienced 10 lb weight loss over that period. On physical examination, the spleen is palpable 6 cm below 5 rest of his examination is normal. Laboratory testing is remarkable for leukocytosis (85 consanguineous marriage. His elder sister is on regular transfusion. Physical examination of the boy shows Pallor, platelet count. 5 02 fotal Marks: 35 Time: 12:00noon Q4. A 47 years woman presented in basic health unit of district Jehlum with complains of fatigue and ROLL NO. WBC 174 x 10⁹/L and platelet count is 24 x 10⁹/L. Pathologist reports 90% blast cells on peripheral film. blood with biomodel peak of neutrophils and myelocytes. There is also increased number of basophils. Which cytochemical stain helps to differentiate between lymphoblast and myeloblast? shows decreased T3 and T4 levels and she is positive for circulating antithyroidantibodies. Haematology Immunology & Research Module Assessment Give any two cytogenetic abnormalities seen in Acute myeloid leukemia. DEPARTMENT OF PATHOLOGY RAWALPINDI MEDICAL UNIVERSITY Differentiate between direct and indirect graft antigen recognition Enumerate 3 types of ELISA with the underlying principle in each disorder. She was diagnosed with immune thrombocytopenic purpura (ITP). Briefly compare the morphology of lymphoblast and myeloblast? What further tests you would like to perform to confirm diagnosis? Classify different types of grafts on the basis of type of donor. Discuss Peripheral film and Bone marrow examination findings. **RMU & Allied Hospitals** of Enlist 4 the different types of antigen antibody reactions rise 3rd Year MBBS SEQs PAPER What advice you would give to the parents of this child? gradual chameratu ovgen vescific autoimmunediseases? Briefly discuss the underlying genetic mutation. transplant but then his condition deteriorated slowly. renal transplant recipient experiences Enlist the causes of thrombocytopenia. What is the most probable diagnosis? Enumerate the phases of this disease. Which type of graft rejection is this? What is your most likelydiagnosis? What is the most likely diagnosis? /Shat () 243nune tolerance? Date: 07th November 2022 the costal margin, the Allowed: 45min technique. (e 9 5 Q3. A p q 0 (P 9 e q 5 (P q 0 (e 9 e à 2 a. **PP**

53 | P a g e

Detailed Analysis of SEQs Paper

| | | | | 1 |
|---------------------|-------------------------|-------|------------|---|
| Levels of cognition | Question number | Total | Percentage | 1 |
| C1 | Sb,6a and 7c | 3 | 16% | |
| C2 | 2b, 2c, 3b, 4a, 4b, 5c, | 8 | 42% | |
| | 6b and 7b | | | |
| | | 0 | 42% | |
| C3 | 1a, 1b, 1c, 2a, 3a, 4c, | 0 | -7 Au 7 O | |

PROF. MOBINA AHSAN DODHY Chairperson, Department of Pathology, RMU ASSISTANT DIRECTOR Department of Medical Education, RMU

VICE CHANCELLOR RAWALPINDI MEDICAL UNIVERSITY

Date: 18th February, 2023 by DME, New Teaching Block

3rd YE

ANNEXURE II

| | | | | 1 | MEDICIN | E | | | | | SURGI | ERY + TR | AUMA | | - |
|------------------------------|--------------------------------|---|-------------------------|---|--|--|--------------------------|--------------------------|--------------------------|---------------------------------------|-------------------------|-------------------------|-------------------------|--------------------------|-------------------------|
| 1 | ates | HFH Unit- | 1 HFH | Unit-11 | BBH Unit | -1 BBI | l Unit-11 | DHQ | HFH Unit | -1 H | FH Unit-11 | | | H Unit-11 | DHO |
| <u>S.P.W</u> <u>S.P.V</u> | 08-02-2023 To 30-04-2023 | To Al | | A2 | | | A4 | A5 | B5 | | B4 | B3 | | B2 | BI |
| <u>s.v</u> | 01-05-2023 To 06-08-2022 | CI | | C2 | C3 | | C4 | C5 | A5 | | A4 | A3 | | A2 | Al |
| | 8-2023 Го 0-2023 | B1 | | B2 | B3 | | B4 | B5 | C5 | | C4 | C3 | | C2 | CI |
| | _ | | | | | 1 | MISCELI | ANEOUS | 3 | | - | | _ | - | 1 |
| | 8-2-23 To 19-2-23 | 20-2-23 To 5-3-23 | 6-3-23 To 19-3-23 | <u>S.P.W</u> 20-3-23 To 9-4-23 | <u>S.P.V</u> 10-4-23 To 30-4-23 | 1-5-23 To 14-5-23 | 15-5-23 To 28-5-23 | 29-5-23 To 11-6-23 | 12-6-23 To 25-6-23 | <u>5.V</u> 26-6-23 To 6-8-23 | 7-8-23 To 20-8-23 | 21-8-23 To 3-9-23 | 4-9-23 To 17-9-23 | 18-9-23 To 1-10-23 | 2-10-2 To 15-10-2 |
| Patholog | v Cl | C2 | C3 | C4 | C5 | B1 | B2 | B3 | B4 | B5 | Al | A2 | A3 | A4 | A5 |
| | | Cl | C2 | C3 | C4 | B5 | B1 | B2 | B3 | B4 | A5 | Al | A2 | A3 | A4 |
| Psychiati | | C1 C5 | Cl | C2 | C3 | B4 | B5 | B1 | B2 | B3 | A4 | A5 | A1 | A2 | A3 |
| Radiolog | y C4 | C.S | 0.000 | | | | B4 | B5 | BI | B2 | A3 | A4 | A5 | Al | A2 |
| Skill La | • C3 | C4 | C5 | Cl | C2 | B3 | | | | B1 | A2 | A3 | A4 | A5 | `AI |
| E.R | C2 | C3 | C4 | C5 | C1 | B2 | B3 | B4 | B5 | BI | AL | | 10220 | | - |
| * | . Soring | lidays Week (S.P.W) Vocations (S.P er Vocations (S | .v) | 12-03-2023 24-04-2023 03-07-2023 | ТО ТО ТО | 19-03-2023 30-04-2023 30-07-2023 | | | | | A | Activat | Swin | Acres | lor |